Dacarbazine medac 1000 mg

DRUG3 trials

Sponsors

University College London, Erasca Inc., Philogen S.p.A.

Conditions

Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.Unresectable or metastatic NRAS mutant cutaneous melanoma stage IA/IIA Hodgkin lymphoma

Phase 2

A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma

Active, not recruitingCTIS2024-512704-20-00

Philogen S.p.A.Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.

Start: 2020-06-22Target: 98Updated: 2025-10-20

Phase 3

RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

RecruitingCTIS2022-500031-37-00

University College London stage IA/IIA Hodgkin lymphoma

Start: 2024-04-08Target: 289Updated: 2025-06-23

A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]

RecruitingCTIS2024-511404-17-00

Erasca Inc.Unresectable or metastatic NRAS mutant cutaneous melanoma

Start: 2024-10-07Target: 294Updated: 2026-01-07